Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients

The identification of predictive biomarkers for antiangiogenic therapies remains an unmeet need. We hypothesized that the transcription factor Homeobox B9 (HOXB9) could be responsible for the tumor resistance to the anti-VEGF agent bevacizumab. HOXB9 expression and activation were measured in eight...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 23; no. 15; pp. 4312 - 4322
Main Authors:	Carbone, Carmine, Piro, Geny, Simionato, Francesca, Ligorio, Francesca, Cremolini, Chiara, Loupakis, Fotios, Alì, Greta, Rossini, Daniele, Merz, Valeria, Santoro, Raffaela, Zecchetto, Camilla, Zanotto, Marco, Di Nicolantonio, Federica, Bardelli, Alberto, Fontanini, Gabriella, Tortora, Giampaolo, Melisi, Davide
Format:	Journal Article
Language:	English
Published:	United States 01.08.2017
Subjects:	Adult Aged Angiopoietin-like Proteins - blood Animals Bevacizumab - administration & dosage Cell Line, Tumor Chemokine CXCL1 - blood Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Disease-Free Survival Drug Resistance, Neoplasm - genetics Female Gene Expression Regulation, Neoplastic - drug effects Homeodomain Proteins - genetics Humans Interleukin-8 - blood Male Mice Middle Aged Neoplasm Metastasis Prognosis Transforming Growth Factor beta - blood Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - genetics
ISSN:	1078-0432, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!